Kainos Medicine, Inc. (KOSDAQ:284620)

Kainos Medicine Statistics

Total Valuation

Kainos Medicine has a market cap or net worth of KRW 35.56 billion. The enterprise value is 37.38 billion.

Market Cap	35.56B
Enterprise Value	37.38B

Important Dates

The next estimated earnings date is Thursday, May 14, 2026.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

Kainos Medicine has 32.71 million shares outstanding. The number of shares has increased by 13.70% in one year.

Current Share Class	32.71M
Shares Outstanding	32.71M
Shares Change (YoY)	+13.70%
Shares Change (QoQ)	+4.75%
Owned by Insiders (%)	22.70%
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	30.35
PB Ratio	7.72
P/TBV Ratio	31.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.80
EV / Sales	31.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.31

Financial Position

The company has a current ratio of 2.19, with a Debt / Equity ratio of 0.03.

Current Ratio	2.19
Quick Ratio	1.57
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	-236.44

Financial Efficiency

Return on equity (ROE) is -121.74% and return on invested capital (ROIC) is -63.90%.

Return on Equity (ROE)	-121.74%
Return on Assets (ROA)	-49.43%
Return on Invested Capital (ROIC)	-63.90%
Return on Capital Employed (ROCE)	-149.12%
Weighted Average Cost of Capital (WACC)	10.28%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

In the past 12 months, Kainos Medicine has paid 2.28 million in taxes.

Income Tax	2.28M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -73.03% in the last 52 weeks. The beta is 1.09, so Kainos Medicine's price volatility has been similar to the market average.

Beta (5Y)	1.09
52-Week Price Change	-73.03%
50-Day Moving Average	1,104.96
200-Day Moving Average	1,939.78
Relative Strength Index (RSI)	50.94
Average Volume (20 Days)	481,084

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kainos Medicine had revenue of KRW 1.17 billion and -7.78 billion in losses. Loss per share was -246.00.

Revenue	1.17B
Gross Profit	170.35M
Operating Income	-6.86B
Pretax Income	-7.78B
Net Income	-7.78B
EBITDA	-6.27B
EBIT	-6.86B
Loss Per Share	-246.00

Balance Sheet

The company has 2.87 billion in cash and 147.28 million in debt, with a net cash position of 2.72 billion or 83.12 per share.

Cash & Cash Equivalents	2.87B
Total Debt	147.28M
Net Cash	2.72B
Net Cash Per Share	83.12
Equity (Book Value)	4.60B
Book Value Per Share	35.01
Working Capital	2.40B

Cash Flow

In the last 12 months, operating cash flow was -5.92 billion and capital expenditures -5.52 million, giving a free cash flow of -5.92 billion.

Operating Cash Flow	-5.92B
Capital Expenditures	-5.52M
Depreciation & Amortization	591.34M
Net Borrowing	-369.63M
Free Cash Flow	-5.92B
FCF Per Share	-181.05

Margins

Gross Margin	14.54%
Operating Margin	-585.84%
Pretax Margin	-664.23%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kainos Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.70%
Shareholder Yield	-13.70%
Earnings Yield	-21.89%
FCF Yield	-16.66%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 24, 2022. It was a reverse split with a ratio of 0.2.

Last Split Date	Jun 24, 2022
Split Type	Reverse
Split Ratio	0.2

Scores

Kainos Medicine has an Altman Z-Score of -19.38 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-19.38
Piotroski F-Score	3